Diagnostic Products Corporation Announces Record Fourth Quarter and Full Year 2005 Results
10 Febbraio 2006 - 2:00PM
Business Wire
Diagnostic Products Corporation (NYSE:DP) today reported fourth
quarter sales of $123.8 million, a 4% increase over the fourth
quarter of 2004. Earnings were $13.1 million, or $.43 per diluted
share, up 17% from $11.1 million or $.37 reported for the fourth
quarter of 2004. The Brazilian Real strengthened relative to the
dollar while the Euro weakened, and the net effect of foreign
currency movements was a 2% decrease in sales. Domestic sales
increased 8% to $38.2 million while international sales grew at 3%.
Sales of IMMULITE products grew 5% over the fourth quarter of 2004.
IMMULITE product line sales reached $114.0 million for the quarter.
IMMULITE reagent sales increased 6% this quarter over the fourth
quarter of 2004 to $95.4 million, and IMMULITE instrument and
service revenue increased by 5% to $18.6 million. Sales of RIA
products were $5.1 million, a 13% decline from last year's fourth
quarter. Sales of other products were $4.7 million, the same as the
fourth quarter last year. Sales for the year ended December 31,
2005 were $481.1 million, an 8% increase over the $446.8 million
recorded in 2004. Net income for the year was $67.2 million, or
$2.23 per diluted share, versus $61.7 million, or $2.06, per share
last year. The Brazilian Real strengthened relative to the dollar
and the Euro weakened slightly, the net effect of foreign currency
was a 2% increase in sales. For the year, IMMULITE product line
sales were $440.4 million, compared to $404.9 million in 2004, an
increase of 9%. Sales of the mature RIA product line were $21.4
million for the year, down 11% from last year. Sales of other
products were $19.3 million for the year, up from $17.8 million in
2004. The Company shipped a total of 256 IMMULITE Instruments in
the fourth quarter, including 184 IMMULITE 2000's and 2500's. The
total number of IMMULITEs shipped is now over 10,900. "While
reagent sales were disappointing we are very pleased with the
number of instruments shipped," said Michael Ziering, CEO of DPC.
"We believe the strong shipments coupled with the release of
certain key assays put us in a very good position going forward."
Diagnostic Products Corporation, founded in 1971, is a global
leader dedicated to immunodiagnostics. DPC's product menu includes
over 75 immunoassays and more than 375 specific allergens and
allergy panels. In addition, DPC addresses the chemistry and
laboratory automation testing needs of its customers through
partnerships with manufacturers of chemistry systems and reagents.
The combined chemistry and immunoassay menu is one of the largest
and most diversified available, covering most laboratory tests
requested. DPC also designs and manufactures automated laboratory
instrumentation, which provides fast, accurate results while
reducing labor and reagent costs. DPC sells its products to
hospitals, clinics and laboratories in more than 100 countries.
Additional Company information can be found on DPC's website at
www.dpcweb.com. Except for the historical information contained
herein, this press release contains forward-looking statements that
involve risks and uncertainties that could cause actual results to
differ materially. These factors include governmental or other
action relating to the Company's Chinese affiliate; the rate of
customer demand for the Company's products; the Company's ability
to successfully market new and existing products; its dependence on
certain suppliers; domestic and foreign government regulation; its
ability to keep abreast of technological innovations and to
translate them into new products; competition; political and
economic instability in certain markets including the movements of
foreign currencies relative to the dollar; and other risks and
uncertainties disclosed from time to time in the Company's SEC
reports and filings. -0- *T DIAGNOSTIC PRODUCTS CORPORATION AND
SUBSIDIARIES CONSOLIDATED STATEMENTS OF INCOME (unaudited) (Amounts
in Thousands, Except Per Share Data) Three Months Ended Year Ended
December 31, December 31, ------------------- -------------------
2005 2004 2005 2004 --------- --------- --------- --------- SALES:
Non-Affiliated Customers $115,879 $110,840 $456,465 $413,952
Unconsolidated Affiliates 7,881 7,819 24,637 32,867 ---------
--------- --------- --------- Total Sales 123,760 118,659 481,102
446,819 COST OF SALES 58,031 58,010 212,690 200,049 ---------
--------- --------- --------- Gross Profit 65,729 60,649 268,412
246,770 OPERATING EXPENSES: Selling 20,062 19,461 79,406 74,599
Research and Development 14,455 11,639 52,097 45,277 General and
Administrative 13,168 15,314 51,288 47,790 Gain on Sale of Product
Line (343) Equity in Income of Affiliates (1,933) (1,914) (9,821)
(8,451) --------- --------- --------- --------- OPERATING
EXPENSES-NET 45,752 44,500 172,627 159,215 --------- ---------
--------- --------- OPERATING INCOME 19,977 16,149 95,785 87,555
Interest/Other Income (Expense)-Net (235) (357) 2,067 450 ---------
--------- --------- --------- INCOME BEFORE INCOME TAXES AND
MINORITY INTEREST 19,742 15,792 97,852 88,005 PROVISION FOR INCOME
TAXES 6,169 4,308 28,485 25,495 MINORITY INTEREST 490 341 2,214 775
--------- --------- --------- --------- NET INCOME $13,083 $11,143
$67,153 $61,735 ========= ========= ========= ========= EARNINGS
PER SHARE: BASIC $0.44 $0.38 $2.29 $2.12 DILUTED $0.43 $0.37 $2.23
$2.06 WEIGHTED AVERAGE SHARES OUTSTANDING: BASIC 29,494 29,181
29,371 29,082 DILUTED 30,147 30,016 30,138 29,910 *T
Grafico Azioni Diagnostic Products (NYSE:DP)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Diagnostic Products (NYSE:DP)
Storico
Da Set 2023 a Set 2024